



NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

NC MEDICAID DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Thursday, July 9, 2026, 1:00 p.m.– 5:00 p.m.
Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. **The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:**

ANALGESICS

1. Opioid Analgesics - Long-Acting Opioids
2. Opioid Analgesics - Short Acting Schedule II Opioids
3. Non-opioid Analgesics
4. NSAIDS
5. Neuropathic Pain

ANTICONVULSANTS

1. Carbamazepine Derivatives
2. Second Generation

ANTI-INFECTIVES – SYSTEMIC

1. Antibiotics - Penicillins, Cephalosporins and Related
2. Antibiotics - Lincosamides and Oxazolidinones
3. Antibiotics - Macrolides and Ketolides
4. Nitroimidazoles (Gastrointestinal Antibiotics)
5. Antifungals
6. Antivirals (General)
7. Antivirals (Hepatitis C Agents)
8. Antivirals (Herpes Treatments)

CARDIOVASCULAR

1. Ace Inhibitor / Diuretic Combinations
2. Angiotensin II Receptor Blocker Diuretic Combinations
3. Antianginal & Anti-ischemic
4. Beta Blockers
5. Cardiovascular, Other

6. Dihydropyridine Calcium Channel Blockers
7. Niacin Derivatives
8. PCSK9
9. Triglyceride Lowering Agents

CENTRAL NERVOUS SYSTEM

1. Antimigraine Agents (CGRP Blocker/Modulators Preventative)
2. Antimigraine Agents (CGRP Blockers/Modulators Acute Treatment)
3. Anti-narcolepsy
4. Multiple Sclerosis (Injectable)
5. Sedative Hypnotics

ENDOCRINOLOGY

1. Glucagon Agents
2. Injectable- Rapid Acting Insulin
3. Long-Acting Insulin
4. Hypoglycemics – Injectable - Premixed 70/30 combination Insulin
5. GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes
6. Alpha-Glucosidase Inhibitors
7. Thiazolidinediones And Combinations
8. Octreotides and Related

GASTROINTESTINAL

1. Bile Acid Salts
2. H. Pylori Combinations
3. Histamine-2 Receptor Antagonists
4. Progestins Used For Cachexia\
5. Proton Pump Inhibitors
6. Selective Constipation Agents
7. Ulcerative Colitis (Oral)
8. Ulcerative Colitis (Rectal)

GENITOURINARY/RENAL

1. Electrolyte Depleters (Kidney Disease)
2. Benign Prostatic Hyperplasia Treatments
3. Urinary Antispasmodics

GOUT

1. Gout

HEMATOLOGIC

1. Anticoagulants (Oral)
2. Colony Stimulating Factors

OPHTHALMIC

1. Allergic Conjunctivitis Agents
2. Anti-inflammatory
3. Prostaglandin Agonists

OSTEOPOROSIS

1. Bone Resorption Suppression and Related Agents

RESPIRATORY

1. Beta-adrenergic Handheld, Short Acting
2. Orally Inhaled Anticholinergics / COPD Agents
3. Inhaled Corticosteroids
4. Intranasal Rhinitis Agents

TOPICALS

1. Acne Agents
2. Androgenic Agents
3. NSAIDS
4. Antibiotics
5. Antibiotics (Vaginal)
6. Antiparasitics
7. Antiviral
8. Psoriasis
9. Steroids (Very High Potency)

BEHAVIORAL HEALTH

1. Antihyperkinesis / ADHD

MISCELLANEOUS

1. Uterine Disorder Treatments
2. GLP-1-Weight Management Agents
3. Immunomodulators, Asthma
4. Immunomodulators, Atopic Dermatitis
5. Estrogen Agents, Oral / Transdermal
6. Cytokine And Cam Antagonists
7. Hereditary Angioedema (Hae) Prophylaxis Agents
8. Potassium_Binders
9. Skeletal Muscle Relaxants
10. Disposable insulin Delivery Devices

Labeler Termination and Obsolete Drugs

1. Labeler Termination: Drugs that are no longer participating in the MDRP
2. Obsolete Drugs: Drugs that are no longer manufactured

- V. Closing comments and adjournment